PD-1

[Seagen, Inc.] Seagen, Inc. and RemeGen Co., Ltd. announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody-drug conjugate.

[Cell] Scientists identified that colorectal cancer manifested with altered ILC3s that were characterized by reduced frequencies, increased plasticity, and an imbalance with T cells.

[Cell] Researchers found that Pin1 was overexpressed both in cancer cells and cancer-associated fibroblasts and correlated with poor survival in pancreatic ductal adenocarcinoma patients.

[Science Translational Medicine] Investigators found that antiangiogenic treatment facilitated non–small cell lung cancer tumor infiltration by PD-1+ regulatory T cells, which were more efficiently targeted by the PD-1 antibody than CD8+ T cells.

[Cellular & Molecular Immunology] The authors generated PD-1 and T cell receptor deficient mesothelin-specific CAR-T cells using CRISPR-Cas9 technology and evaluated them in a dose-escalation study.

[Nature Communications] Scientists showed that the deubiquitinase USP12 was commonly downregulated in the KrasG12D-driven mouse lung tumour and human non-small cell lung cancer owing to the activation of AKT-mTOR signalling.